CHMP Backs First Anti-CGRP in Europe for Migraine

If approved, rimegepant would be the first CGRP receptor antagonist available in Europe and the only migraine medication approved for both acute and preventive treatment in adults.
International Approvals

source https://www.medscape.com/viewarticle/969451?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

Heart Failure Care Outside of ICU Can Lower Cost